EUCTR2012-002073-60-GB进行中（未招募）1 期
iraglutide in PCOS (LIPOS) Study: Evaluation of the Efficacy of Liraglutide on Menstrual Cyclicity in Women with PCOS - a prospective randomised double-blind placebo-controlled study - Liraglutide in PCOS
niversity of Warwick0 个研究点目标入组 80 人开始时间: 2012年12月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. PCOS diagnosis defined according to all three criteria of the 2003 Rotterdam Consensus Group: (i) Menstrual disorders, either amenorrhoea or less than six menses in the last 12 months; (ii) Clinical or biochemical hyperandrogenism, once secondary causes such as hyperprolactinaemia, Cushing’s syndrome, congenital adrenal hyperplasia have been excluded; (iii) Polycystic ovaries on ultrasound scan
- •2. Informed consent obtained before any study related activities
- •3. Body Mass Index (BMI) > 27 kg/m2 and BMI < 45 kg/m2
- •4. Stable body weight (less than 5 kg self-reported change) during the previous 3 months
- •5. Age: = 18 years and < 40 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 106
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Any clinically significant disease which in the Investigator's opinion could interfere with the safety of study participants or with the results of the study
- •2. Diagnosis (already documented diagnosis or new diagnosis based on the OGTT results at study visit 2) of Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) or Type 2 Diabetes Mellitus (diagnosis based on the American Diabetes Association criteria on the diagnosis and classification of diabetes mellitus)
- •3. Previous treatment with GLP-1 receptor agonists (including liraglutide or exenatide) or drugs that affect gastrointestinal motility or carbohydrate metabolism, or lipid-lowering or anti-obesity drugs within the last 3 months
- •4. Pregnancy, breast-feeding or intention to become pregnant or not using adequate contraceptive methods (adequate contraceptive measures defined as consistent use of barrier methods or true abstinence).
- •5. Obesity induced by other endocrinological disorders (e.g. Cushing Syndrome). The presence of other endocrinopathies will have been ruled out at the time of PCOS diagnosis.
- •6. Current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic corticosteroids (except for a short course of treatment, i.e. 7-10 days), atypical antipsychotic, tricyclic antidepressants, and mood stabilizers (e.g., amitryptiline, imipramine, mirtazapin, phenelzine, paroxetine, thioridazine, clorpromazine, olanzapine, clozapine, lithium and valproic acid and its derivatives,)
- •7. Participation in a clinical trial of weight control within the last 3 months prior to screening
- •8. Current participation in an organised diet reduction programme (or within the last 3 months) and/or are currently using or have used within three months before screening: orlistat, pramlintide, zonisamide, topiramate (either by prescription or as part of a clinical trial)
- •9. Any intervention that would alter weight and therefore interfere with menstrual cyclicity, such as: (i) Diet attempts using herbal supplements or over-the-counter medications within 3 months before screening; (ii) Previous surgical treatment for obesity (excluding liposuction if performed more than one year before this study)
- •10. Surgery scheduled for the study duration period, except for minor surgical procedures, at the discretion of the Investigator
- •11. History of major depressive disorder or history of other severe psychiatric disorders, e.g. schizophrenia or bipolar disorder within the last 2 years
- •12. Untreated or uncontrolled hypothyroidism/hyperthyroidism defined as TSH > 6 mIU/L or < 0.4 mIU/L, respectively
- •13. Impaired liver function, defined as ALAT =2.5 times upper limit of normal
- •14. Impaired renal function defined as serum-creatinine =110 µmol/L (= 1.3 mg/dL) or according to local label for metformin use
- •15. Known clinically significant active cardiovascular disease, including history of unstable angina, acute coronary event, other significant cardiac events (including history of myocardial infarction, arrhythmias, or conduction delays on electrocardiogram), or cerebral stroke within the last 6 months and/or heart failure (New York Heart Association Class III and IV) at the discretion of the
研究者
相似试验
进行中（未招募）
1 期
Prevention of early cardiovascular disease in Polycystic Ovary syndromePolycystic Ovary Syndrome (PCOS), especialy signs of early cardiovascular disease in women with PCOS.MedDRA version: 14.1Level: LLTClassification code 10065161Term: Polycystic ovarian syndromeSystem Organ Class: 100000004872EUCTR2013-003862-15-DKJens Faber
尚未招募
3 期
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and InfertilityPolycystic Ovary SyndromeInfertility, FemaleObesityNCT05952882Mỹ Đức Hospital188
尚未招募
不适用
Insulin sentizier for PCOS women undergoing ICSIPACTR201308000579176Hassan Aly Hassan Elmeghraby220
招募中
4 期
Liraglutide Treatment in Obese Infertile PCOS WomenPCOSInfertilityObesityNCT06742710Peking University Third Hospital890
进行中（未招募）
1 期
Effect of liraglutide for weight management in children with Prader-Willi SyndromeObesity(Prader-Willi syndrome)MedDRA version: 18.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-004415-37-FRovo Nordisk A/S60